The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis

Minerva Anestesiologica

Volumn 76, Issue 10, 2010, Pages 787-794

  Tsantes, A ^a   Tsangaris, I ^a   Nikolopoulos, G ^b   Bagos, P ^c   Kopterides, P ^a   Antonakos, G ^a   Dimopoulou, I ^a   Vrioni, G ^d   Kapsimali, V ^d   Dima, K ^a   Armaganidis, A ^a   Travlou, A ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Center for Disease Control and Prevention   (Greece)

^c UNIVERSITY OF CENTRAL GREECE   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Homocysteine; Sepsis; Shock, septic

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PROTEIN C;

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOOD ANALYSIS; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

ACTIVATED PROTEIN C RESISTANCE; AGED; BLOOD COAGULATION TESTS; COHORT STUDIES; COMORBIDITY; FACTOR V; FEMALE; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTINURIA; HOSPITAL MORTALITY; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUSCLE SPASTICITY; POINT MUTATION; PROTEIN C; PSYCHOTIC DISORDERS; RESPIRATION, ARTIFICIAL; SEPSIS; SHOCK, SEPTIC; THROMBOPHILIA; VITAMIN B 12;

EID: 78149235775     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Wheeler A P, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
2. Dellinger R P, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
3. Levi M, Keller T T, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26-39.
4. Polli F, Savioli M, Cugno M, Taccone P, Bellani G, Spanu P et al. Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control. Minerva Anestesiol 2009;75:417-26.
5. Matsuda N, Hattori Y. Vascular biology in sepsis: pathophys-iological and therapeutic significance of vascular dysfunction. J Smooth Muscle Res 2007;43:117-37.
6. Villar J, Flores C, Pérez-Méndez L, Blanco J, Muros M. Genetic determinants of survival in sepsis and acute lung injury. Minerva Anestesiol 2008;74:341-5.
7. Texereau J, Pene F, Chiche JD, Rousseau C, Mira J P. Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32:S313-S9.
8. Eldibany ME, Caprini JA. Hyperhomocysteinemia and thrombosis. An overview. Arch Pathol Lab Med 2007;131:872-84.
9. Rodgers GM, Kane WH. Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986;77:1909-16.
10. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895-901.
11. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine J Clin Invest 1991;88:1906-14.
12. Hayashi TG, Honda G, Suzuki K. An atherogenic stimulus, homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-6.
13. Fryer RH, Wilson BD, Gubler BD, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993;13:1327-33.
14. Tofler GH, D'Agostino RB, Jacques PF, Bostom AG, Wilson PW, Lipinska I et al. Association between increased homo-cysteine levels and impaired fibrinolytic potential; potential mechanism for cardiovascular risk. Thromb Haemost 2002; 88:799-804.
15. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma HC affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006;26:1397-404.
16. Schindler K, Zauner C, Buchmayer H, Fodinger M, Woifl G, Bieglmayer C et al. High prevalence of hyperhomocys-teinemia in critically ill patients. Crit Care Med 2000;28: 991-5.
17. Ridker PM, Hennekens CH, Selhub J, Miletich J P, Malinow MR. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777-82.
18. Undas A, Williams EB, Butenas S, Orfeo T, Mann KG. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001;276:4389-97.
19. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation 1998;98:2520-6.
20. Schuerholz T, Marx G. Management of sepsis. Minerva Anestesiol 2008;74:181-95.
21. Levy MM, Fink M, Marshall JC, Abraham E, Angus D, Cook D et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31: 1250-6.
22. Komitopoulou A, Platokouki H, Kapsimali Z, Pergantou H, Adamtziki E, Aronis S. Mutations and polymorphisms in genes affecting hemostasis proteins and homocysteine metabolism in children with arterial ischemic stroke. Cerebrovasc Dis 2006;22:13-20.
23. Dahaba AA, Metzler H. Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? Minerva Anestesiol 2009;75:447-52.
24. Payen D, Faivre V, Lukaszewicz AC, Villa F, Goldberg P. Expression of monocyte human leukocyte antigen-DR in relation with sepsis severity and plasma mediators. Minerva Anestesiol 2009;75:484-93.
25. Zarychanski R, Houston SD. Plasma HC concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability. Thrombosis Haemostasis 2004;916:1115-22.